Marco is a biochemist with a strong expertise in Chemical Biology & Drug Development. In his PhD thesis he developed novel methods for fragment-based drug discovery. It was honored by the German Chemical Society with the Klaus Grohe Prize of Medicinal Chemistry. Afterwards he joined the University Chemical Laboratory Cambridge UK, working for the Bill & Melinda Gates Foundation on novel anti-tuberculosis drugs. During his stay at the University of Cambridge Marco was awarded with a prestigious Marie Curie Fellowship of the European Commission for the development of a novel drug class targeting RNA interference. After returning to Germany he co-founded biotx.ai, a company that develops novel statistical tools for efficacy prediction of drug candidates from population data. biotx.ai has received multiple awards for its machine learning technology specifically designed for the analysis of biomedical data.
Marco provides almost a decade of experience in the biotech ecosystem. He is the author of the textbook “Chemical Biology & Drug Discovery”.
Dr Christine Natasha Ryan holds a PhD in Neuroscience from the University of Cambridge, Cambridge, UK and an MBA from Stockholm School of Economics. Following a post-doc at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark, Dr Ryan remained in Scandinavia moving to Sweden to work at Astra, which then became AstraZeneca, holding line management and competitive intelligence roles. Dr Ryan has engaged in preclinical research at blue chip companies such as AstraZeneca, smaller pharmaceutical companies, CROs and biotechs, working at Karo Bio AB, and Cerca Insights among others. Dr Ryan joined Gabather AB as Principal Scientist in 2017, becoming VP Operations in 2018. She is currently COO.
CEO Dr Michael-Robin Witt holds a Ph.D. in Neuropharmacology from the Royal School of Pharmacy, Copenhagen, Denmark. He has published more than 50 publications in peer-reviewed scientific journals. Following 12 years in academic research, at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark. MRW has held senior line and project management positions in Scandinavian Biotech companies including Neurosearch AB (1999-2000), AstraZeneca R&D (2000-2003), KaroBio AB (2003-2007). In 2007, MRW co-founded Axcentua Pharmaceuticals AB, acting as CSO for 5 years before joining Lead Discovery Malaysia in 2012 where he currently holds the positions of CEO & CSO. MRW joined Gabather AB in September 2014 and was appointed Principal Scientist in October 2015. He is currently CEO.
A leader with nearly 20 years of experience in Research and Development in the pharmaceutical industry:
Alexion’s (AstraZeneca Rare Disease) Vice President, Global Head of Country Operations Management, Patryk is accountable for driving transformative improvement in the delivery of Alexion Sponsored clinical trial programs and leading the country operations team providing oversight of clinical studies conducted at sites across the Alexion portfolio worldwide.
Patryk was with AstraZeneca for 17 years where he started in 2003, holding various operational and strategic positions: Vice President of the Management Board in 2018-2020, Regional Director Europe for Research and Development in 2016-2020 – both at AstraZeneca Pharma Poland sp. z o.o. Earlier, he had developed his competences in the foreign branches of AstraZeneca in Sweden and Germany and managed and co-founded a Clinical Research Department in Ukraine.
Patryk Mikucki is a graduate of the Faculty of Veterinary Medicine in Lublin with the title of Doctor of Veterinary Sciences and PhD in Epizootiology. He is an author of several scientific publications in this field. Moreover, he is a graduate of the Warsaw-Illinois Executive MBA.
With a broad background as cancer rehabilitation specialist through exercise referral,
Natacha is an EUPATI fellow with significant experience in patient advocacy and
patient education in the field of cancer. Before joining Lymphoma Coalition in 2017,
she had successfully held Patient and Public affairs roles in cancer charities in Spain
since 2011. Natacha was appointed Board Member of ECPC from 2016 to 2017 and is
currently Chair of EBMT Patient Advocacy Committee, and member of EHA´s European
Affairs Committee, ESMO Patient Advocacy Working Group, GoCART Coalition and
contributes to other projects at European level, as Harmony Alliance, T2EVOLVE, and
RESILIENCE.
Natacha is a true believer in the power of cooperation. She has worked at a national
and European level with multi-stakeholders’ partnerships, educational groups, and she
is deeply interested remove barriers to access to care for patients with lymphoma and
to improving the quality of life for patients. Natacha has contributed to Health
Technology Appraisal processes and is frequently invited to provide the patient
perspective in different scenarios. In addition to the role at EU level, she is currently
member of the Institutional Working Group on the Plan to Access Advanced Therapies
in the National Health System in Spain.
Zvezda Lauric comes from a journalism background with multiple appearances on various television channels across Latin America. Her passion for educating people in medical cannabis comes from a personal connection with her mother being ill – she quickly understood that the cannabis plant can be used as a powerful medicine. Today, she is working on removing the stigmas around cannabis and also supporting women in the industry, hoping that more women will have the courage to break barriers in the cannabis industry
Ian Greenfield helped transform Oregon’s healthcare delivery system while serving in Governor John A. Kitzhaber, MD’s administration. He has held leadership positions in numerous companies and non-profit organizations, including the world’s leading death with dignity advocacy group, Compassion & Choices. His marketing work has earned both an International Association of Business Communicators’ Bronze Beacon Award and a Public Relations Society of America Award of Excellence.
Uber Health provides a modern, tech-enabled logistics platform that is designed to expand access to reliable transportation, deliveries, and meals. Our mission is to enable patients from all demographics to have equal access to healthcare, and to reduce work for staff by giving them tools that optimize their time. Our partnerships arm focuses on engaging organizations that are looking to improve recruitment, retention, and overall experience for both patients & medical staff.
Dr. Greene is a seasoned pharmaceutical research professional with success both in large pharmaceutical companies and in CROs. He has a PhD and post-doctoral training in psychology and neuroscience, with a focus on the neuroanatomical and neurochemical bases of learning and memory. His career has spanned the full range of clinical development from preclinical pharmacology through late-stage clinical development, successful NDA and MAA submissions, and post approval commitments and label extensions. Dr. Greene has published numerous manuscripts and over thirty abstracts, all focused in CNS research from the bench to clinical work.
With over 25 years of experience in the pharmaceutical industry, first as a Lilly Fellow at the Universitè Louis Pasteur in Strasbourg, France, Paul has obtained roles of progressing responsibility at major pharmaceutical companies and CROs. He has experience across a range of CNS disease states with very deep concentrations in mood disorders and schizophrenia. He has worked extensively in pediatric and elderly populations including special institutional environments. At GlaxoSmithKline Dr. Greene led the clinical team through the creation and execution of a clinical development plan for a major marketed product for bipolar disorder. He also led the submission team for a successful NDA and MAA for that product and wrote the Integrated Summary of Efficacy and the Integrated Summary of Benefits and Risks.
Having led global project management teams, a rater training enterprise, and large customer relationships at Syneos Health, Dr. Greene brings scientific, operational, and partnership expertise to the relationships in his remit. Paul is Senior Vice President, Global Client Solutions at Syneos Health.
